Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine PK in Adolescents
NCT00113594Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of olanzapine in schizophrenia and bipolar I disorder, sponsored by Eli Lilly and Company. Primary endpoints: Pharmacokinetic parameters, Inter- and intra-subject variabilities of pharmacokinetics and 1 more. Started Jun 2005; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT00113594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113594.